<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04528849</url>
  </required_header>
  <id_info>
    <org_study_id>E1-20-377</org_study_id>
    <nct_id>NCT04528849</nct_id>
  </id_info>
  <brief_title>Comparison of Ovulation Induction Cycle Outcomes Between Early and Late Dose Increments for Low Dose Gonadotropin Step-up Protocol Among Infertile Women Diagnosed With Polycystic Ovary Syndrome: Prospective Randomised Trial</brief_title>
  <official_title>Comparison of Ovulation Induction Cycle Outcomes Between Early and Late Dose Increments for Low Dose Gonadotropin Step-up Protocol Among Infertile Women Diagnosed With Polycystic Ovary Syndrome: Prospective Randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saglik Bilimleri Universitesi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saglik Bilimleri Universitesi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low dose gonadotropin step-up ovulation induction treatment is the universally accepted and&#xD;
      utilized teratment protocol for infertile women diagnosed with polycystic ovary syndrome&#xD;
      (PCOS). First dose increment is advised on 14th day of ovarian stimulation with gonadotropins&#xD;
      to decrease multiple follicle generation and cycle cancellation rates. However, clinicians&#xD;
      impatiently increase gonadotropin dose on 7th day of stimulation without strong scientific&#xD;
      evidence. This randomised controlled study will be the first study which will compare safety&#xD;
      and ovulation induction cyle outcomes of early and late dose increments among infertile women&#xD;
      diagnosed with PCOS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Low dose gonadotropin step-up ovulation induction treatment is the universally accepted and&#xD;
      utilized teratment protocol for infertile women diagnosed with polycystic ovary syndrome.&#xD;
      First dose increment is advised on 14th day of ovarian stimulation with gonadotropins to&#xD;
      decrease multiple follicle generation and cycle cancellation rates. However, clinicians&#xD;
      impatiently increase gonadotropin dose on 7th day of stimulation without strong scientific&#xD;
      evidence. This randomised controlled study will be the first study which will compare safety&#xD;
      and ovulation induction cyle outcomes of early and late dose increments among infertile women&#xD;
      diagnosed with polycystic ovary syndrome.&#xD;
&#xD;
      We will start low dose step-up ovulation induction treatment by using 50 IU recombinant FSH&#xD;
      for 21-39 years old non- obese patients (BMI &lt;30 kg/m2) diagnosed with PCOS and . We will&#xD;
      perform folliculometry on 7th day of ovulation induction. In case of absence for at least one&#xD;
      &gt;10 mm dominant follicle, we will randomise these women by using blind envelope selection&#xD;
      method for assignment of early or late dose incerement groups. Half of the patients will&#xD;
      receive 25 IU dose increment on 7th day of ovulation induction, remaining half will receive&#xD;
      dose increment on 14th day of ovulation induction. We will continue ovarian stimulation&#xD;
      without any other dose increment until 35th day of stimulation as deadline time restriction.&#xD;
      We will perform folliculometry and serum estradiol measurement intermittently during&#xD;
      ovulation induction. We will record ovulation induction cycle outcomes and clinical pregnancy&#xD;
      results of the study group following finalization for treatment cyle of each patient. We will&#xD;
      compare ovulation induction cycle outcomes of these two dose increment groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2020</start_date>
  <completion_date type="Anticipated">August 20, 2022</completion_date>
  <primary_completion_date type="Actual">August 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of preovulatory follicles</measure>
    <time_frame>35 days</time_frame>
    <description>Number of &gt;14 mm sized follicles at the end of the ovulation induction treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy rate</measure>
    <time_frame>2 weeks after ovulation triggering</time_frame>
    <description>Serum pregnancy test will be performed 2 weeks after ovulation triggering</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>3 weeks after ovulation triggering</time_frame>
    <description>Clinical pregnancy rate which will be evaluated 3 weeks after ovulation triggering</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cycle length in days</measure>
    <time_frame>7-35 days</time_frame>
    <description>Total number of ovulation induction days until ovulation triggering</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cycle cancellation</measure>
    <time_frame>35 days</time_frame>
    <description>Cycle cancellation due to &gt;=3 preovulatory follicles (&gt;14 mm in size) at the end of the ovulation induction treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple pregnancy rate</measure>
    <time_frame>3 weeks after ovulation triggering</time_frame>
    <description>Multiple pregnancy rate which will be evaluated 3 weeks after ovulation triggering</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Early dose increment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who have received 25 IU gonadotropin dose increment on 7th day of ovulation induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late dose increment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who have received 25 IU gonadotropin dose increment on 14th day of ovulation induction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadotropin dose increment timing</intervention_name>
    <description>Gonadotropin dose increments of 25 IU will be utilized on 7th and 14th day of ovulation induction for each study group.</description>
    <arm_group_label>Early dose increment</arm_group_label>
    <arm_group_label>Late dose increment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Infertile women who have been diagnosed with PCOS based on Rotterdam&#xD;
        criteriae and who have not succeeded to get pregnant by using oral ovulation induction&#xD;
        agents and whose BMI levels are &lt;30 kg/m2 will be included to the study.&#xD;
&#xD;
        Exclusion Criteria:Infertile women with tubal diseases, male factor infertility,&#xD;
        endometriosis, previous pelvic surgery history, chronic systemic disease, BMI levels&gt;30&#xD;
        kg/m2 and who are not voluntary to attend to the study will be excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serkan Kahyaoglu, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ankara City Hospital, Department of Reproductive Endocrinology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Serkan Kahyaoglu, M.D</last_name>
    <phone>+905058868040</phone>
    <email>serkan.kahyaoglu@sbu.edu.tr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Health Sciences, Ankara City Hospital, Department of Reproductive Endocrinology</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serkan Kahyaoglu, M.D</last_name>
      <phone>+905058868040</phone>
      <email>serkan.kahyaoglu@sbu.edu.tr</email>
    </contact>
    <investigator>
      <last_name>Serkan Kahyaoglu, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inci Kahyaoglu, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Omer H Yumusak, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Berna Seckin, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hacer C Gulerman, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Muzeyyen G Ozaksit, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ozlem Moraloglu Tekin, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/16759926/</url>
    <description>Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low-dose step-up protocol with weekly increments of 25 international units of follicle-stimulating hormone</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/30013434/</url>
    <description>Pilot study of the optimal protocol of low dose step-up follicle stimulating hormone therapy for infertile women</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/14664878/</url>
    <description>Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saglik Bilimleri Universitesi</investigator_affiliation>
    <investigator_full_name>Serkan Kahyaoglu</investigator_full_name>
    <investigator_title>Associate Professor, M.D</investigator_title>
  </responsible_party>
  <keyword>Polycystic ovary syndrome</keyword>
  <keyword>Infertility</keyword>
  <keyword>Low dose step-up</keyword>
  <keyword>Gonadotropin</keyword>
  <keyword>Ovulation induction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

